In the largest prospective study of patients with primary mediastinal B-cell lymphoma, radiation therapy was omitted in complete responders to immunochemotherapy without compromising outcomes. These findings were presented at the 2023 ASCO Annual Meeting.
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma. Patients treated with the chimeric antigen receptor T-cell therapy experienced a 27.4% relative reduction in mortality as compared with patients receiving high-dose therapy and auto-HCT.
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the results of the phase III SWOG S1826 trial presented at the 2023 ASCO Annual Meeting.1 The addition of nivolumab to the regimen of doxorubicin, vinblastine, and dacarbazine (AVD) was associated with about a 52% reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in patients from ages 12 to 83.
In the phase I/II BRUIN trial reported in The New England Journal of Medicine, Anthony R. Mato, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib exhibited strong activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had received prior treatment with a covalent BTK inhibitor.
Investigators have found that patients who had depression and/or anxiety prior to their diagnosis of diffuse large B-cell lymphoma (DLBCL) may have had shorter survival times than patients who didn’t have a mental health condition prior to their DLBCL diagnosis, according to a new study published by Kuczmarski et al in The Lancet Haematology. The findings point to an urgent need for systematic mental health assessments and interventions for patients with DLBCL.